Contrast-enhanced mr imaging of two superparamagnetic res-contrast agents: Functional assessment of experimental radiation-induced liver injury

Journal of Magnetic Resonance Imaging

Volumn 10, Issue 1, 1999, Pages 52-56

  Stiskal, Michael ^a   Demsar, Franci ^a   Mühler, Andreas ^b   Schwickert, Heidi C ^c   Roberts, Timothy P L ^c   Szolar, Dieter ^d   Fischer, Hardo ^a   Brasch, Robert C ^c  

^a KH Lainz ^*  (Austria)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF GRAZ   (Austria)

Author keywords

Contrast media; Experimental model; Iron particles; Liver contrast enhancement; Magnetic resonance imaging (MRI); Radiation hepatitis

Indexed keywords

CONTRAST MEDIUM; DDM 128; DEXTRAN; FERRIC OXIDE; NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ELECTRON SPIN RESONANCE; HEPATITIS; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LIVER INJURY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PION; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RAT; RETICULOENDOTHELIAL SYSTEM; X IRRADIATION;

ANIMALS; CONTRAST MEDIA; FERRIC COMPOUNDS; HEPATITIS, ANIMAL; IMAGE ENHANCEMENT; IRON; LIVER; MAGNETIC RESONANCE IMAGING; MALE; OXIDES; PARTICLE SIZE; POWDERS; RADIATION INJURIES, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032807713     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199907)10:1<52::AID-JMRI7>3.0.CO;2-C     Document Type: Article

References (21)

1. Vogl TJ, Hammerstingl R, Schwarz W, et al. Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions. Radiology 1996;198:881-887.
2. Petersein J, Saini S, Weissleder R. Liver II: iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. MRI Clin North Am 1996;4:53-60.
3. Kopp AF, Laniado M, Dammann F, et al. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties. Radiology 1997;204:749-756.
4. Vogl TJ, Hammerstingl R, Schwarz W, et al. Magnetic resonance imaging of focal liver lesions: comparison of the superparamagnetic iron oxide Resovist versus gadolinium-DTPA in the same patient. Invest Radiol 1996;31:696-708.
5. Saini S, Edelman RR, Sharma P, et al. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR 1995;164:1147-1152.
6. Weissleder R, Hahn PF, Stark DD, Elizondo G, Saini S, Todd LE, Wittenberg J, Ferrucci JT. Superparamagnetic iron oxide: enhanced detection of splenic tumors with MR imaging. Radiology 1988;169: 399-403.
7. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR 1989;152:167-173.
8. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-493.
9. Weissleder R, Papisov M. Pharmaceutical iron oxides for MR imaging. Magn Reson Med 1992;4:1-20.
10. Reimer P, Weissleder R, Lee AS, Buettner S, Wittenberg J, Brady TJ. Asialoglycoprotein receptor function in benign liver disease: evaluation with MR imaging. Radiology 1991;178:769-774.
11. Mühler A, Bauer H, Brasch RC, Weinmann HJ. Semiquantitative evaluation of RES activity in experimental hepatic injury using superparamagnetic iron particles. In: Proceedings of the SMRI Annual Meeting, San Francisco, 1993.
12. Pouliquen D, Le Jeune JJ, Perdrisot R, Ermias A, Jallet P. Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolism. Magn Reson Imaging 1991;9:275-283.
13. Schaffer BK, Linker C, Papisov M, et al. MION-ASF: biokinetics of an MR receptor agent. Magn Reson Imaging 1993;11:411-417.
14. Mandeville JB, Moore J, Chesler DA, Garrido L, Weissleder R, Weisskoff RM. Dynamic liver imaging with iron oxide agents: effects of size and biodistribution on contrast. Magn Reson Med 1997;37: 885-890.
15. Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ, Ferrucci JT Jr. Ferrite particles: superparamagnetic MR contrast agent for the reticuloeendothelial system. Radiology 1987;162:211-217.
16. Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ, Ferrucci JT, Jr. Principles. AJR 1991;156:236-239.
17. Stiskal M, Schwickert HC, Demsar F, et al. Contrast enhancement in experimental radiation-induced liver injury: comparison of hepatocellular and reticuloendothelial particulate contrast agents. J Magn Reson Imaging 1996;6:286-290.
18. Clement O, Mühler A, Vexler VS, et al. Evaluation of radiation-induced liver injury with MR imaging: comparison of hepatocellular and reticuloendothelial contrast agents. Radiology 1992;185:163-168.
19. Weissleder R, Reimer P, Lee AS, Wittenberg J, Brady TJ. MR receptor imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors. AJR 1990;155:1161-1167.
20. Lawaczek R, Bauer H, Frenzel T, et al. Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting: pre-clinical profile of SH U555A. Acta Radiol 1997;38: 584-597.
21. Elizondo G, Weissleder R, Stark D, et al. Hepatic cirrhosis and hepatitis: MR Imaging enhanced with superparamagnetic iron oxide. Radiology 1990;174:797-801.